登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月24日，First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-25

  • First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

    Hongyi Chen, Zhicheng Zhang, Li Wang, Zhihua Huang, Fanghua Gong, Xiaodong Li, Yahong Chen, Jinzi J. WU

    doi: https://doi.org/10.1101/2020.03.22.20034041

    Abstract

    As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in China in January, 2020, repurposing approved drugs is emerging as important therapeutic options. We reported here the first clinical study using hepatitis C virus (HCV) protease inhibitor, danoprevir, to treat COVID-19 patients. Danoprevir (Ganovo) is a potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved and marketed in China since 2018 to treat chronic hepatitis C patients. Ritonavir is a CYP3A4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus (HIV) protease inhibitor at high doses.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1
15浏览量
原文链接
相关报告

  • 《3月24日_丹诺瑞韦治疗初治和经治的COVID-19患者的首项临床研究》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-25
    • 信息名称：丹诺瑞韦治疗初治和经治的COVID-19患者的首项临床研究 1.时间：2020年3月24日 2.机构或团队：中国南昌市第九医院传染病科 3.事件概要： 中国南昌市第九医院传染病科科研人员在medRxiv预印本平台发表论文“First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients”。文章旨在研究丹诺瑞韦（Danoprevir）联合利托那韦（Ritonavir）治疗COVID-19的效果。 该小样本临床研究结果显示，丹诺瑞韦（Danoprevir）联合利托那韦（ritonavir）治疗在所有患者中的安全性和耐受性良好。经过4-12天达诺瑞韦联合利托那韦治疗后，11例患者（包含2位初治患者和9位经治患者）全部达到以下四项标准后出院：（1）体温恢复正常3天以上；（2）呼吸道症状明显好转；（3）肺部影像学显示急性渗出性病变明显改善；（4）连续两次呼吸道标本核酸检测阴性（采样时间至少间隔1天）。 4.附件： 原文链接：https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1
    89浏览量
    原文链接

  • 《MedRxiv，3月24日，Analysis of psychological state and clinical psychological intervention model of patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-25
    • Analysis of psychological state and clinical psychological intervention model of patients with COVID-19 Lu Yang, Danjuan Wu, Yanbin Hou, Xunqiang Wang, Ni Dai, Guanjun Wang, Qing Yang, Wenhui Zhao, Zhongze Lou, Yunxin Ji, Liemin Ruan doi: https://doi.org/10.1101/2020.03.22.20040899 Abstract Background:Patients with the 2019 coronavirus disease (COVID-19) have different degrees of psychological pain, such as anxiety and depression, which may related to their prognosis. Psychological intervention can be conducted in different ways to improve psychological pain and improve the treatment effect. Objective:The present study aimed to investigate and analyze the psychological status of patients with COVID-19 during the course of illness, and to evaluate the effect and influencing factors of psychological crisis intervention, so as to explore the effective mode of clinical psychological intervention in acute patients under isolation environment. Methods:A total of 143 persons participated in the study, including 26 patients diagnosed with COVID-19 in the isolation ward (COVID-19 group), 87 patients with general pneumonia in the observation ward (General Pneumonia group) and 30 healthy volunteers (Normal group). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    12浏览量
    原文链接